Overview: Fusion Transcript TestIntroduction: The Fusion Transcript Test detects genetic fusion transcripts to diagnose cancers like leukemia, helping guide targeted therapy for abnormal cell growth. Affecting 1 in 100,000 people with leukemia, these cancers pose diagnostic challenges due to genetic complexity. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses RT-PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in oncology.
Other Names: Fusion Gene Test, Leukemia Transcript Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Fusion transcript testing began in the 1990s with research by Rowley, who identified chromosomal translocations. RT-PCR/sequencing advancements in the 2000s by Illumina improved detection, surpassing earlier karyotyping methods.
Purpose: Detects fusion transcripts to diagnose leukemia or other cancers, guides targeted therapy, and evaluates patients with abnormal blood counts, aiming to improve survival.
Test Parameters: Fusion transcript presence
Pretest Condition: Tissue or bone marrow biopsy required. Collect tissue or blood. Report history of cancer symptoms.
Specimen: Tissue (FFPE, 0.5-2 cma³), Whole Blood (EDTA, 3-5 mL); Tissue or bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document fatigue or abnormal blood counts. Include current medications or cancer history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., relapse), and sample collection risks.
Procedural Considerations: Uses RT-PCR/sequencing to detect fusions, requiring labs with thermal cyclers or sequencers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive transcripts confirm cancer, guiding therapy. Early treatment might improve prognosis, while untreated cases lead to progression. Negative results may require biopsy.
Specialist Consultation: Consult an oncologist for interpretation.
Additional Supporting Tests: Bone marrow biopsy, cytogenetics, or FISH to confirm diagnosis.
Test Limitations: Specific to tested transcripts; correlation with symptoms needed. False negatives possible with rare fusions.
References: NCCN Guidelines, 2023; Blood, Rowley JD, 2022.
